

Peer Review File

Article information: <https://dx.doi.org/10.21037/tbcr-23-15>

Reviewer Comments

Reviewer A

Comment: This is an important as well as timely issue. While the authors correctly point out that the various new methods for determining HER2 positivity still require larger clinical validation as well as correlation with HER2-directed treatment outcomes it is very helpful to clinicians to understand the various methodologies as well as their strengths and weaknesses.

Reply: Thank you for your careful review of our manuscript. I have made modifications and additions to the manuscript. Thank you very much for your comment.

Reviewer B

Comment: This manuscript provides a comprehensive and concise overview about HER2 low assessment status in breast cancer. High interobserver variability in HER2 low scoring needs further improvements either by using new test methods or optimization of HER2 expression assessment. With respect to the latter authors refer to own encouraging data making use of AI based digital image analysis.

I agree to their conclusions and have no further comments.

Reply: Thank you for your careful review of our manuscript. I have made modifications and additions to the manuscript. Thank you very much for your comment.